BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

907 related articles for article (PubMed ID: 26209749)

  • 1. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer.
    Teng F; Meng X; Kong L; Mu D; Zhu H; Liu S; Zhang J; Yu J
    Transl Res; 2015 Dec; 166(6):721-732.e1. PubMed ID: 26209749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD8+ and FOXP3+ tumor-infiltrating T cells before and after chemoradiotherapy for rectal cancer.
    Shinto E; Hase K; Hashiguchi Y; Sekizawa A; Ueno H; Shikina A; Kajiwara Y; Kobayashi H; Ishiguro M; Yamamoto J
    Ann Surg Oncol; 2014 Jun; 21 Suppl 3():S414-21. PubMed ID: 24566864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoradiation-Induced Alteration of Programmed Death-Ligand 1 and CD8
    Lim YJ; Koh J; Kim S; Jeon SR; Chie EK; Kim K; Kang GH; Han SW; Kim TY; Jeong SY; Park KJ; Wu HG
    Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1216-1224. PubMed ID: 29165286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-Infiltrating Lymphocytes in Biopsy Specimens Obtained 7 Days after Starting Chemoradiotherapy for Rectal Cancer Are Predictors of the Response to Chemoradiotherapy.
    Miyakita H; Sadahiro S; Suzuki T; Chan LF; Ogimi T; Okada K; Yamamoto S; Kajiwara H
    Oncology; 2020; 98(12):869-875. PubMed ID: 32799200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
    Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between the expressions of PD-L1 and tumor-infiltrating lymphocytes in oral squamous cell carcinoma.
    Cho YA; Yoon HJ; Lee JI; Hong SP; Hong SD
    Oral Oncol; 2011 Dec; 47(12):1148-53. PubMed ID: 21911310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
    Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
    Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTLA-4 Synergizes With PD1/PD-L1 in the Inhibitory Tumor Microenvironment of Intrahepatic Cholangiocarcinoma.
    Guo XJ; Lu JC; Zeng HY; Zhou R; Sun QM; Yang GH; Pei YZ; Meng XL; Shen YH; Zhang PF; Cai JB; Huang PX; Ke AW; Shi YH; Zhou J; Fan J; Chen Y; Yang LX; Shi GM; Huang XY
    Front Immunol; 2021; 12():705378. PubMed ID: 34526987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer.
    Baretti M; Zhu Q; Fu W; Meyer J; Wang H; Anders RA; Azad NS
    Oncotarget; 2022; 13():907-917. PubMed ID: 35937503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
    Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
    Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
    Zhang L; Wang XI; Ding J; Sun Q; Zhang S
    Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Implications of Cytotoxic T Lymphocyte Antigen-4 Expression on Tumor Cells and Tumor-Infiltrating Lymphocytes in Extrahepatic Bile Duct Cancer Patients Undergoing Surgery Plus Adjuvant Chemoradiotherapy.
    Lim YJ; Koh J; Kim K; Chie EK; Kim S; Lee KB; Jang JY; Kim SW; Oh DY; Bang YJ
    Target Oncol; 2017 Apr; 12(2):211-218. PubMed ID: 28084572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1/PD-L1 expression in a series of intracranial germinoma and its association with Foxp3+ and CD8+ infiltrating lymphocytes.
    Liu B; Arakawa Y; Yokogawa R; Tokunaga S; Terada Y; Murata D; Matsui Y; Fujimoto KI; Fukui N; Tanji M; Mineharu Y; Minamiguchi S; Miyamoto S
    PLoS One; 2018; 13(4):e0194594. PubMed ID: 29617441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.
    Berghoff AS; Ricken G; Widhalm G; Rajky O; Dieckmann K; Birner P; Bartsch R; Höller C; Preusser M
    Histopathology; 2015 Jan; 66(2):289-99. PubMed ID: 25314639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas.
    Soeratram TT; Creemers A; Meijer SL; de Boer OJ; Vos W; Hooijer GK; van Berge Henegouwen MI; Hulshof MC; Bergman JJ; Lei M; Bijlsma MF; Ylstra B; van Grieken NC; van Laarhoven HW
    J Pathol; 2022 Mar; 256(3):282-296. PubMed ID: 34743329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between tumor microenvironment-associated factors and the efficacy and prognosis of neoadjuvant therapy for rectal cancer.
    Zhang S; Bai W; Tong X; Bu P; Xu J; Xi Y
    Oncol Lett; 2019 Jan; 17(1):1062-1070. PubMed ID: 30655866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study.
    Miyashita M; Sasano H; Tamaki K; Hirakawa H; Takahashi Y; Nakagawa S; Watanabe G; Tada H; Suzuki A; Ohuchi N; Ishida T
    Breast Cancer Res; 2015 Sep; 17(1):124. PubMed ID: 26341640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.